Firsocostat is a selective inhibitor of the enzyme farnesyl pyrophosphate synthase and belongs to the class of dihydroimidazopyrimidine derivatives. Currently investigated for its potential in cancer treatment,… Read more
Firsocostat is a selective inhibitor of the enzyme farnesyl pyrophosphate synthase and belongs to the class of dihydroimidazopyrimidine derivatives. Currently investigated for its potential in cancer treatment, this compound functions by blocking the post-translational modification necessary for cell division and protein synthesis. Laboratories involved in pharmaceutical development and preclinical research rely on high-quality reference standards, including the parent drug and stable isotope labelled compounds such as Firsocostat-13C-d3, to ensure the accuracy of their analytical workflows. These materials are critical for precise quantitative analysis, metabolite identification, and method validation using mass spectrometry and chromatographic techniques. By utilizing these characterized reference materials, researchers can effectively perform impurity profiling and monitor metabolic pathways, ensuring the integrity of data throughout the drug development process.